about
Hepatitis C virus infection influences the S-methadone metabolite plasma concentrationDissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance.Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.Weighted evidence approach of bridging study.Assessment of regional treatment effect in a multiregional clinical trial.Putative tumor metastasis-associated genes in human gastric cancer.Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.Design and analysis of non-inferiority mortality trials in oncology.Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients.A 12-year ecological study of hip fracture rates among older Taiwanese adults.Proposals of statistical consideration to evaluation of results for a specific region in multi-regional trials--Asian perspective.OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study.Sample size determination for a specific region in a multiregional trial.CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients.Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.A consistency approach to evaluation of bridging studies and multi-regional trials.On non-inferiority analysis based on delta-method confidence intervalsMixed noninferiority margin and statistical tests in active controlled trialsImpaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic controlEstablishing consistency across all regions in a multi-regional clinical trialValidation of the Chinese-Canadian study of health and aging clinical frailty scale (CSHA-CFS) telephone versionA consistency approach for evaluation of biosimilar productsMulticentre, Phase II Study of Gemcitabine and S-1 in Patients with Advanced Biliary Tract Cancer: TG1308 Study
P50
Q28534782-7722F044-BBAF-4B78-8A0E-23F591B61F5FQ37008823-69AC6DF1-487B-4F2E-B291-076E3867B792Q37199426-EF940027-C11C-4928-98F9-0D4743943EDCQ38040494-871D4587-67CF-4907-B7B3-988280499943Q38040501-A49AEE42-8853-4FFB-9B45-6D0B718E3661Q39337214-3BBB6817-D250-48B7-8B78-22F1627CC917Q39379211-DA84B03C-C914-437E-BC53-9183FD694DB6Q42788954-2E18988E-CF1D-4AE2-AEA0-9A0A0D598422Q44273770-065E5C70-1D87-4B62-85E3-E9F76E1182C6Q44333249-4B0AF94D-2421-4385-BE1A-CD56684B9799Q45201182-61560AAB-ADDA-40FC-95DB-85E9722BF05FQ45344326-3165ABC2-7003-4BB7-BB1D-3DFC816CFB0BQ46961507-A72F6B84-CB21-4BB8-B2C5-3952D6F91985Q47430820-187FC49E-C88C-4859-B8D7-99743B663253Q47998145-004A49A5-B787-4F34-ACB1-268E59F67D4FQ49032684-9B935DFF-A61A-4FC8-ADBC-808A513323F1Q50255389-6D609C88-2913-420C-AEE7-9DB5CB604360Q50787650-8E9A74F0-F446-4E75-ADCF-587DFAA54E67Q50797242-EE3765CA-ED9C-411C-A785-B25D48A3482FQ51567739-1FDF98C8-A1D5-4231-BEBE-D0D94B6D4C2EQ73815339-D56CE75F-055A-42CC-9DD4-B8746C34B116Q79964775-573BB586-9F22-4585-A9FF-C1D780D39C02Q83832897-9DBB92BD-42AF-4F45-B09A-00F213E3712BQ83894269-53B99063-B6F9-4C99-B1B9-5D81777C6941Q84240840-072232F2-EA8E-46B5-B4A1-EAAD7E7E78B9Q87275635-9312C76D-FDCC-4D64-85C0-235AEA1BE1F5Q95942203-0B5CC3C7-7F64-4D7B-9BF3-97D74EACD841
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hsiao-Hui Tsou
@ast
Hsiao-Hui Tsou
@en
Hsiao-Hui Tsou
@es
Hsiao-Hui Tsou
@nl
Hsiao-Hui Tsou
@sl
type
label
Hsiao-Hui Tsou
@ast
Hsiao-Hui Tsou
@en
Hsiao-Hui Tsou
@es
Hsiao-Hui Tsou
@nl
Hsiao-Hui Tsou
@sl
prefLabel
Hsiao-Hui Tsou
@ast
Hsiao-Hui Tsou
@en
Hsiao-Hui Tsou
@es
Hsiao-Hui Tsou
@nl
Hsiao-Hui Tsou
@sl
P1053
E-3837-2010
P106
P1153
14122558200
P31
P3829
P496
0000-0001-6773-4111